365 related articles for article (PubMed ID: 29856501)
41. Distinct promoters induce APOBEC-1 expression in rat liver and intestine.
Greeve J; Axelos D; Welker S; Schipper M; Greten H
Arterioscler Thromb Vasc Biol; 1998 Jul; 18(7):1079-92. PubMed ID: 9672068
[TBL] [Abstract][Full Text] [Related]
42. The implications of APOBEC3-mediated C-to-U RNA editing for human disease.
Van Norden M; Falls Z; Mandloi S; Segal BH; Baysal BE; Samudrala R; Elkin PL
Commun Biol; 2024 May; 7(1):529. PubMed ID: 38704509
[TBL] [Abstract][Full Text] [Related]
43. RNA binding to APOBEC deaminases; Not simply a substrate for C to U editing.
Smith HC
RNA Biol; 2017 Sep; 14(9):1153-1165. PubMed ID: 27869537
[TBL] [Abstract][Full Text] [Related]
44. C-->U editing of apolipoprotein B mRNA in marsupials: identification and characterisation of APOBEC-1 from the American opossum Monodelphus domestica.
Fujino T; Navaratnam N; Jarmuz A; von Haeseler A; Scott J
Nucleic Acids Res; 1999 Jul; 27(13):2662-71. PubMed ID: 10373583
[TBL] [Abstract][Full Text] [Related]
45. APOBEC3 genes: retroviral restriction factors to cancer drivers.
Henderson S; Fenton T
Trends Mol Med; 2015 May; 21(5):274-84. PubMed ID: 25820175
[TBL] [Abstract][Full Text] [Related]
46. Somatic hypermutation in immunity and cancer: Critical analysis of strand-biased and codon-context mutation signatures.
Steele EJ
DNA Repair (Amst); 2016 Sep; 45():1-24. PubMed ID: 27449479
[TBL] [Abstract][Full Text] [Related]
47. APOBEC: From mutator to editor.
Yang B; Li X; Lei L; Chen J
J Genet Genomics; 2017 Sep; 44(9):423-437. PubMed ID: 28964683
[TBL] [Abstract][Full Text] [Related]
48. Low expression of the apolipoprotein B mRNA-editing transgene in mice reduces LDL levels but does not cause liver dysplasia or tumors.
Qian X; Balestra ME; Yamanaka S; Borén J; Lee I; Innerarity TL
Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):1013-20. PubMed ID: 9633945
[TBL] [Abstract][Full Text] [Related]
49. Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.
Pautasso S; Galitska G; Dell'Oste V; Biolatti M; Cagliani R; Forni D; De Andrea M; Gariglio M; Sironi M; Landolfo S
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045985
[TBL] [Abstract][Full Text] [Related]
50. Intracellular trafficking determinants in APOBEC-1, the catalytic subunit for cytidine to uridine editing of apolipoprotein B mRNA.
Yang Y; Sowden MP; Yang Y; Smith HC
Exp Cell Res; 2001 Jul; 267(2):153-64. PubMed ID: 11426934
[TBL] [Abstract][Full Text] [Related]
51. Epstein-Barr virus and malaria upregulate AID and APOBEC3 enzymes, but only AID seems to play a major mutagenic role in Burkitt lymphoma.
Summerauer AM; Jäggi V; Ogwang R; Traxel S; Colombo L; Amundsen E; Eyer T; Subramanian B; Fehr J; Mantel PY; Idro R; Bürgler S
Eur J Immunol; 2022 Aug; 52(8):1273-1284. PubMed ID: 35503749
[TBL] [Abstract][Full Text] [Related]
52. The evolution of apolipoprotein B and its mRNA editing complex. Does the lack of editing contribute to hypertriglyceridemia?
Damsteegt EL; Davie A; Lokman PM
Gene; 2018 Jan; 641():46-54. PubMed ID: 29031774
[TBL] [Abstract][Full Text] [Related]
53. APOBEC3 mutational signatures are associated with extensive and diverse genomic instability across multiple tumour types.
Jakobsdottir GM; Brewer DS; Cooper C; Green C; Wedge DC
BMC Biol; 2022 May; 20(1):117. PubMed ID: 35597990
[TBL] [Abstract][Full Text] [Related]
54. Insulin increases expression of apobec-1, the catalytic subunit of the apolipoprotein B mRNA editing complex in rat hepatocytes.
von Wronski MA; Hirano KI; Cagen LM; Wilcox HG; Raghow R; Thorngate FE; Heimberg M; Davidson NO; Elam MB
Metabolism; 1998 Jul; 47(7):869-73. PubMed ID: 9667237
[TBL] [Abstract][Full Text] [Related]
55. Research on the influence of APOBEC family on the occurrence, diagnosis, and treatment of various tumors.
Yang J; Hou J; Li M
J Cancer Res Clin Oncol; 2023 Jan; 149(1):357-366. PubMed ID: 36222899
[TBL] [Abstract][Full Text] [Related]
56. DNA deamination in immunity: AID in the context of its APOBEC relatives.
Conticello SG; Langlois MA; Yang Z; Neuberger MS
Adv Immunol; 2007; 94():37-73. PubMed ID: 17560271
[TBL] [Abstract][Full Text] [Related]
57. Clinical Implications of APOBEC3-Mediated Mutagenesis in Breast Cancer.
Roelofs PA; Martens JWM; Harris RS; Span PN
Clin Cancer Res; 2023 May; 29(9):1658-1669. PubMed ID: 36478188
[TBL] [Abstract][Full Text] [Related]
58. Phosphorylation is a regulatory mechanism in apolipoprotein B mRNA editing.
Chen Z; Eggerman TL; Patterson AP
Biochem J; 2001 Aug; 357(Pt 3):661-72. PubMed ID: 11463337
[TBL] [Abstract][Full Text] [Related]
59. Apolipoprotein B RNA editing enzyme-deficient mice are viable despite alterations in lipoprotein metabolism.
Morrison JR; Pászty C; Stevens ME; Hughes SD; Forte T; Scott J; Rubin EM
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7154-9. PubMed ID: 8692961
[TBL] [Abstract][Full Text] [Related]
60. Determinants involved in regulating the proportion of edited apolipoprotein B RNAs.
Sowden M; Hamm JK; Spinelli S; Smith HC
RNA; 1996 Mar; 2(3):274-88. PubMed ID: 8608451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
